Dividend stocks can be powerful components of a well-diversified income portfolio. AT&T and AbbVie are two popular blue chip dividend stocks known for their high yields.

In the realm of investment, pharma dividend stocks are a beacon for both stability and growth. This sector not only enhances the quality of life on a global scale but also presents lucrative opport...

In the latest trading session, AbbVie (ABBV) closed at $154.04, marking a -0.54% move from the previous day.

Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 66 Aristocrats, screened as of December 12, 202...

Stocks of a lot of well-known and historically great companies are on sale right now. Many marquee names haven't shared in this year's market rally and are in the red for 2023.

Although investors have some evidence of a possible economic recovery, they should still consider defensive stock picks. We just don't know what will happen next.

AbbVie is buying ImmunoGen to pocket its antibody drug conjugate (ADC) assets. Pfizer just did the same thing with Seagen on a much larger scale.

Last week, AbbVie announced a plan to acquire the Massachusetts-based biotechnology company in an all-cash deal worth $8.7 billion. Cerevel, which specializes in treatments for brain diseases, fini...

AbbVie announced two major acquisitions in seven days. Buying ImmunoGen and Cerevel Therapeutics should make AbbVie more competitive in oncology and neuroscience.

AbbVie offers an above-average dividend yield and its payout has risen sharply in recent years. Medical Properties Trust slashed its dividend in half this year and it still offers an enormous 12.6%...

On Dec. 6, AbbVie agreed to acquire Cerevel Therapeutics for $8.7 billion. On Nov. 30, AbbVie announced a $10.1 billion acquisition of ImmunoGen.

Healthcare stocks are a great way for investors to achieve long-term wealth creation. The healthcare sector is essential to solving some of the world's most pressing issues from heart disease, Alzh...

Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.

AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several ri...